Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Kidney Cancer (July 2020)

Posted by Matt Breese on Jul 31, 2020

Find me on:

According to our recent payer coverage analysis for kidney cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for kidney cancer treatments shows that under the pharmacy benefit, about 62% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Kidney Cancer-3Q2020Data snapshot as of Q3 2020

Trends: In December 2019, the FDA approved Teva Pharmaceuticals USA, Inc.'s and Endo International plc unit Par Pharmaceuticals' everolimus for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer in postmenopausal women; advanced renal cell carcinoma; renal angiomyolipoma and tuberous sclerosis complex; progressive neuroendocrine tumors of pancreatic origin; and progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are unresectable.  

To read the full Reality Check on Kidney Cancer treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing